/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Zai Lab Ltd Share Price Today: Live Updates & Key Insights

Zai Lab Ltd share price today is $18.87, up -1.05%. The stock opened at $18.61 against the previous close of $19.07, with an intraday high of $19.035 and low of $18.44.

Zai Lab Ltd Share Price Chart

style
pb-0

Zai Lab Ltd

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Zai Lab Ltd Share Price Performance

$18.87 -0.0105(-1.05%) ZLAB at 13 Mar 2026 04:01 PM Biotechnology
Lowest Today 18.44
Highest Today 19.035
Today’s Open 18.61
Prev. Close 19.07
52 Week High 44.34
52 Week Low 15.96
Day’s Range: Low 18.44 High 19.035
52-Week Range: Low 15.96 High 44.34
1 day return -
1 Week return -3.43
1 month return -5.89
3 month return +8.8
6 month return -40.96
1 year return -47.87
3 year return -40.55
5 year return -86.75
10 year return -

Zai Lab Ltd Institutional Holdings

RTW INVESTMENTS, LLC 6.21

Capital World Investors 5.42

ClearBridge Advisors, LLC 3.14

HHG PLC 1.83

Frazier Life Sciences Management, L.P. 1.70

FMR Inc 1.29

BAMCO Inc 1.27

ADAR1 Capital Management LLC 1.11

Baron Emerging Markets Institutional 1.05

Baron Emerging Markets Strategy 1.05

Citadel Advisors Llc 0.88

T. Rowe Price Associates, Inc. 0.85

Allianz Asset Management AG 0.73

Rock Springs Capital Management LP 0.72

Wellington Management Company LLP 0.67

MPM Oncology Impact Management LP 0.66

iShares Biotechnology ETF 0.55

RTW Biotech Opportunities Ord 0.55

Fidelity Growth Compy Commingled Pl S 0.46

CAM Group Holding A/S 0.46

C WorldWide Healthcare Select 1A 0.46

BlackRock Inc 0.42

T. Rowe Price Health Sciences 0.41

B Group, Inc 0.36

Legal & General Group PLC 0.35

Walleye Trading Advisors, LLC 0.33

Fidelity Growth Company Fund 0.30

UBS Group AG 0.27

abrdn World Healthcare 0.18

Fidelity China Region 0.15

Fidelity Pacific Basin 0.15

International Biotechnology Ord 0.14

Fidelity Growth Company K6 0.12

Wellington Intl Small Cap Research 0.11

Tema Oncology ETF 0.11

Vanguard International Explorer Inv 0.09

ALPS Medical Breakthroughs ETF 0.09

Baron International Growth Retail 0.08

Baron International Growth Strategy 0.08

Fidelity Series Growth Company 0.08

Zai Lab Ltd Market Status

Strong Buy: 7

Buy: 4

Hold: 1

Sell: 0

Strong Sell: 0

Zai Lab Ltd Fundamentals

Market Cap 2109.92 M

PB Ratio 2.9489

PE Ratio 0.0

Enterprise Value 1665.85 M

Total Assets 1172.38 M

Volume 596949

Zai Lab Ltd Company Financials

Annual Revenue FY23:263490000 263.5M, FY22:215040000 215.0M, FY21:144312000 144.3M, FY20:48958000 49.0M, FY19:12984751 13.0M

Annual Profit FY23:171987000 172.0M, FY22:141022000 141.0M, FY21:92073000 92.1M, FY20:32222000 32.2M, FY19:9235945 9.2M

Annual Net worth FY23:-300960000 -301.0M, FY22:-481994000 -482.0M, FY21:-692444000 -692.4M, FY20:-298162000 -298.2M, FY19:-183365894 -183.4M

Quarterly Revenue Q3/2025:116095000 116.1M, Q2/2025:109977000 110.0M, Q1/2025:106487000 106.5M, Q3/2024:102265000 102.3M, Q2/2024:100504000 100.5M

Quarterly Profit Q3/2025:69212000 69.2M, Q2/2025:66757000 66.8M, Q1/2025:67840000 67.8M, Q3/2024:65348000 65.3M, Q2/2024:65271000 65.3M

Quarterly Net worth Q3/2025:-35963000 -36.0M, Q2/2025:-40727000 -40.7M, Q1/2025:-48438000 -48.4M, Q3/2024:-41671000 -41.7M, Q2/2024:-80277000 -80.3M

About Zai Lab Ltd & investment objective

Company Information Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Turning Point Therapeutics, Inc. to develop and commercialize products containing repotrectinib; Entasis Therapeutics Holdings Inc. to develop and commercialize Durlobactam with Sulbactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for Tisotumab Vedotin. The company was incorporated in 2013 and is based in Pudong, China.

Organisation Biotechnology

Employees 1784

Industry Biotechnology

CEO Dr. Ying Du Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow